menu
    • menu
    [{"orgOrder":0,"company":"Enzyvant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Processed Thymus Tissue","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Enzyvant","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzyvant \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Enzyvant \/ Inapplicable"},{"orgOrder":0,"company":"Enzyvant","sponsor":"Aceragen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Recombinant Human Acid Ceramidase","moa":"Acid ceramidase","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Enzyvant","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzyvant \/ Aceragen","highestDevelopmentStatusID":"5","companyTruncated":"Enzyvant \/ Aceragen"}]

    Find Clinical Drug Pipeline Developments & Deals by Enzyvant

    Menu

    Enzyvant

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enzyvant

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Enzyvant

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Processed Thymus Tissue

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerati...

                            Details : RETHYMIC® (allogeneic processed thymus tissue-agdc), one-time regenerative tissue-based therapy for immune reconstitution in pediatric with congenital athymia. RETHYMIC is engineered human thymus tissue designed to regenerate thymic function children wi...

                            Product Name : Rethymic

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 10, 2021

                            Lead Product(s) : Allogeneic Processed Thymus Tissue

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enzyvant

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Enzyvant

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Acid Ceramidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Aceragen

                            Deal Size : $226.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease

                            Details : ACG-801 is an investigational form of recombinant human acid ceramidase (rhAC) designed to address the genetic deficiency of the naturally occurring enzyme which is the cause of Farber disease and Spinal Muscular Atrophy with Progressive Myoclonic Epilep...

                            Product Name : ACG-801

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            March 05, 2021

                            Lead Product(s) : Recombinant Human Acid Ceramidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Aceragen

                            Deal Size : $226.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth